No attempt to associate either CTC or platelet PD-L1 expression and outcomes was performed, since patients were enrolled based on convenience and represented a vast heterogeneity of breast cancer subtypes, treatments, lines of therapy, and follow-up. The gene discussed is CD274; the disease is breast carcinoma.